15/01/2024 – AB Science today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating severe systemic mastocytosis with its lead compound masitinib, based on findings from study AB06006 Download PDF Post navigationPreviousPrevious post:AB Science webcast – Masitinib in Sickle Cell DiseaseNextNext post:AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines AgencyRelated PostsRevenues for the first half of 2024 and update on AB Science’s activitiesOctober 10, 2024AB Science announces the completion of settlement and delivery of its latest capital increase of 5.0 million eurosOctober 9, 2024AB Science announces a slight delay in the publication of its 2024 half-year financial reportSeptember 30, 2024AB Science announces the success of a 5.0 million euros capital increaseSeptember 30, 2024AB Science provides an update on the microtubule program AB8939September 26, 2024AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024September 23, 2024
AB Science announces the completion of settlement and delivery of its latest capital increase of 5.0 million eurosOctober 9, 2024
AB Science announces a slight delay in the publication of its 2024 half-year financial reportSeptember 30, 2024
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024September 23, 2024
